BioSpace News Archive

WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, announced it has secured $10 million in growth capital financing from existing investors, LKCM Headwater Investments, the private equity arm of Luther King Capital Management which is an SEC-registered investment adviser with approximately $24.7 billion in assets under management.

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the second of two Phase 3 (ESSENCE-2) studies, evaluating the investigational drug CyclASol® to treat the signs and symptoms of dry eye disease DED, has been completely enrolled with a total of 834 participants.

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021.

HAYA Therapeutics today announced the formation and members of its Scientific Advisory Board (SAB).

Prolacta Bioscience is proud to announce the company’s senior director of advocacy and government affairs, Carolyn TenEyck, RN, was honored with the Lifetime Achievement Award from the National Black Nurses Association (NBNA) for her remarkable contributions to improving the lives of numerous patient groups over the last 20 years, including premature and critically ill infants.

Desktop Health, a healthcare business within Desktop Metal, Inc. committed to developing 3D printing and biofabrication solutions for personalized medicine, announced the expansion of its dental technology portfolio to include a turnkey metal 3D printing solution for dentistry along with the launch of chrome cobalt for use in dental applications.

PHASE Scientific International LTD (PHASE Scientific), a high-growth biotech company founded by bioengineers from UCLA, today announced that its INDICAID™ COVID-19 Rapid Antigen Test (INDICAID) received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on July 29, 2021.

AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces that it will present “Drug Reimbursement Strategies for 21st Century Cures” at the IDN and Bio/Pharma Partnering Summit, Aug. 19, 11:15 a.m.–12 p.m. EDT.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.